Rational design of antirheumatic prodrugs specific for sites of inflammation.

about

Postmarketing surveillance evaluating the safety and effectiveness of golimumab in Japanese patients with rheumatoid arthritis.The making of bispecific antibodies

P2860

Q38741139-AFC01BA5-6A65-4AD4-9984-28B39B12E0DC Q42323236-49F008B8-C6DC-4993-93C3-18290DBFF537

P2860

Rational design of antirheumatic prodrugs specific for sites of inflammation.

Item

http://www.wikidata.org/entity/Q36799824

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Rational design of antirheumatic prodrugs specific for sites of inflammation.

@ast

Rational design of antirheumatic prodrugs specific for sites of inflammation.

@en

type

Item

label

Rational design of antirheumatic prodrugs specific for sites of inflammation.

@ast

Rational design of antirheumatic prodrugs specific for sites of inflammation.

@en

prefLabel

Rational design of antirheumatic prodrugs specific for sites of inflammation.

@ast

Rational design of antirheumatic prodrugs specific for sites of inflammation.

@en

P1476

Rational design of antirheumatic prodrugs specific for sites of inflammation.

@en

P2093

Costantino Pitzalis

http://www.w3.org/2001/XMLSchema#string

Daniele Sblattero

http://www.w3.org/2001/XMLSchema#string

Shimobi C Onuoha

http://www.w3.org/2001/XMLSchema#string

P2860

A general method of in vitro preparation and specific mutagenesis of DNA fragments: study of protein and DNA interactions

Bispecific antibodies for cancer therapy: the light at the end of the tunnel?

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

Structural Basis for Treating Tumor Necrosis Factor (TNF )-associated Diseases with the Therapeutic Antibody Infliximab

Comparison of the Inhibition Mechanisms of Adalimumab and Infliximab in Treating Tumor Necrosis Factor α-Associated Diseases from a Molecular View

Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II

Matrix metalloproteinases in tuberculosis.

Identification of synovium-specific homing peptides by in vivo phage display selection.

Immunolocalisation studies on six matrix metalloproteinases and their inhibitors, TIMP-1 and TIMP-2, in synovia from patients with osteo- and rheumatoid arthritis.

Determination of interstitial collagenase (MMP-1) in patients with rheumatoid arthritis.

P304

2661-2672

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ART.39232

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Mathieu Ferrari

P577

2015-06-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26097196

http://www.w3.org/2001/XMLSchema#string

P932

4832285

http://www.w3.org/2001/XMLSchema#string

Rational design of antirheumatic prodrugs specific for sites of inflammation.

about

P2860

P2860

Rational design of antirheumatic prodrugs specific for sites of inflammation.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932